EAM
TSBX

Eventide Asset Management’s Turnstone Biologics TSBX Stock Holding History

Eventide Asset Management’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-458,317
Closed -$1.2M – 194
2024
Q2 		$1.2M Hold
458,317
– – 0.02% 157
2024
Q1 		$1.2M Sell
458,317
-250,000
-35% -$716K 0.02% 151
2023
Q4 		$1.8M Hold
708,317
– – 0.03% 142
2023
Q3 		$2.79M Buy
+708,317
New +$6.31M 0.05% 139

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Eventide Asset Management's TSBX Position: Q3 2024 in Review

Eventide Asset Management sold out of Turnstone Biologics (TSBX) in Q3 2024, closing a stake of 458,317 shares — an estimated $1.2M sold.

Eventide Asset Management first reported a position in TSBX in Q3 2023 and held it in 4 quarters. The position peaked at $2.79M in Q3 2023. 24 funds tracked by Wall St. Rank hold TSBX as of Q3 2024.

  • Eventide Asset Management reported no remaining Turnstone Biologics position as of Q3 2024 after selling out during the quarter.
  • Eventide Asset Management sold 458,317 Turnstone Biologics shares in Q3 2024, an estimated $1.2M.
  • Eventide Asset Management first reported a position in Turnstone Biologics in Q3 2023 and held it in 4 quarters.
  • Eventide Asset Management's Turnstone Biologics position peaked at $2.79M in Q3 2023.
  • 24 funds tracked by Wall St. Rank held Turnstone Biologics as of Q3 2024.

Based on Eventide Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.